Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States

Published:2021-01-01 Issue:1 Volume:24 Page:421-431
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Simons Claire L.¹^ORCID,Malone Daniel²^ORCID,Wang Michael³^ORCID,Maglinte Gregory A.⁴^ORCID,Inocencio Tim⁵^ORCID,Wade Sally W.⁶^ORCID,Bennison Craig¹^ORCID,Shah Bijal⁷^ORCID

Affiliation:

1. Pharmerit – An OPEN Health Company, York, UK

2. L. S. Skaggs Research Institute, The University of Utah College of Pharmacy, Salt Lake City, UT, USA

3. Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4. Kite, a Gilead Company, Santa Monica, CA, USA

5. Pharmerit – An OPEN Health Company, Bethesda, MD, USA

6. Wade Outcomes Research and Consulting, Salt Lake City, UT, USA

7. Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1894158

Reference50 articles.

1. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011

2. National Cancer Institute. SEER Cancer Statistics review: Non-Hodgkin Lymphoma. [Internet]. 2020; [cited 2020 Oct 1]. Available from: https://seer.cancer.gov/csr/1975_2016/results_merged/sect_19_nhl.pdf.

3. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma

4. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas

5. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review;Value in Health;2024-08

2. Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas;Frontiers in Oncology;2024-07-01

3. FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges;Current Pharmaceutical Biotechnology;2023-10-04

4. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma;Investigational New Drugs;2023-08-12

5. Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands;Frontiers in Oncology;2023-06-28